| Name | Title | Contact Details |
|---|---|---|
Carlos Ng |
Vice President of Information Technology | Profile |
Sean Riley |
Chief Information Officer | Profile |
DirectRx is an independent pharmacy dedicated to providing patients with unparalleled, personalized pharmaceutical care. At DirectRx Pharmacy, the patient, physician and pharmacy form a circle of integrated services and coordinated care. There are no gaps in patient care between physician and pharmacy, because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our sense of urgency and commitment to unparalleled customer care makes DirectRx unique in the marketplace. We are large enough to provide the full range of pharmaceutical solutions and medications required to optimally treat chronic disease states, yet small enough to care that each patient stays on their prescribed regimen and receives the support they need throughout the course of their treatment. We believe in innovative ideas. Breaking traditional methods, DirectRx has an integration of care between the patient and the provider including a support system for the patient, from help with financial assistance to expert advice on how to manage the complicated drug regimens. DirectRx is accredited by NABP, ACHC, URAC and WBENC. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. As a family-owned business, the company has grown to serve more than 20 states since its inception more than two decades ago. Investments in technology help to provide clients with accurate, timely orders at competitive prices. DirectRx is led by founder and CEO Santa Zawaideh, R.Ph., who has been in private, independent practice since 1980. She is the proud recipient of the Michigan Pharmacist Association`s Governor`s Award and former two-term president of the Oakland County Pharmacy Association. Vice President of Clinical Services Amanda Berishaj, Pharm. D., daughter of Zawaideh, oversees the daily operations of DirectRx, as well as the clinical operations of patients with chronic disease states.
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Velocity Clinical Research, headquartered in Durham, NC, is a leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. The company has 18 sites across 12 US States. We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 5500 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality.
Vincerx Pharma is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.